Results 231 to 240 of about 120,822 (295)

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper   +27 more
wiley   +1 more source

Diagnostic Yield and Clinical Utility of Chromosomal Microarray Analysis (CMA) in Children With Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder: A Systematic Review. [PDF]

open access: yesCureus
Abdelgayoum Ahmed MO   +7 more
europepmc   +1 more source

Hormonal Therapy Before Micro‐TESE in Men With Nonobstructive Azoospermia: A Negative Answer to an Overly Broad Question

open access: yes
Andrology, EarlyView.
Sandro C. Esteves   +4 more
wiley   +1 more source

Satellite DNA evolution in Tytonidae (Aves: Strigiformes): dynamic repeat landscapes despite conserved karyotypes. [PDF]

open access: yesChromosome Res
Bitencourt FL   +10 more
europepmc   +1 more source

Author's Response: Can Hormonal Therapy Improve the Outcomes of mTESE in Patients with Nonobstructive Azoospermia?

open access: yes
Andrology, EarlyView.
M. Anfosso   +5 more
wiley   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy